Bridging the gap from evidence to policy and practice: Reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 5, 2013, Pages 435-442

  Eapen, Valsamma ^a,b   Shiers, David ^c   Curtis, Jackie ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Infant Child and Adolescent Mental Health Service   (Australia)

^c Retired GP and Initiative to Reduce the Impact of Schizophrenia   (United Kingdom)

^d Eastern Suburbs Mental Health Programme   (Australia)

Author keywords

Adolescents; Antipsychotics; Children; Metabolic syndrome; Monitoring; Policy; Practice guidelines; Weight gain

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; ZIPRASIDONE;

BIOLOGICAL MONITORING; CHILD PSYCHIATRY; DISEASE COURSE; HEALTH CARE POLICY; HUMAN; METABOLIC SYNDROME X; MORBIDITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENTS; ANTIPSYCHOTICS; CHILDREN; METABOLIC SYNDROME; MONITORING; POLICY; PRACTICE GUIDELINES; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; METABOLIC SYNDROME X; OBESITY; PSYCHOTIC DISORDERS;

EID: 84880531228     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867412463169     Document Type: Review

References (71)

1. ADA-APA (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry 65: 267-272.
2. Alberti KG and Zimmet P (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 15: 539-553.
3. Alberti KG, Zimmet P and Shaw J (2005) The metabolic syndrome-A new worldwide definition. Lancet 366: 1059-1062.
4. Allison DB, Mackell JA and McDonnell DD (2003) The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services 54: 565-567.
5. Allison DB, Mentore JL, Heo M, et al. (1999) Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 156: 1686-1696.
6. Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, et al. (2008a) Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: A systematic critical reappraisal. CNS Drugs 22: 547-562.
7. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, et al. (2008b) Nonpharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials. British Journal of Psychiatry 193: 101-107.
8. Bernardo M, Canas F, Banegas JR, et al. (2009) Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: A crosssectional study in a low cardiovascular disease risk geographical area. European Psychiatry 24: 431-441.
9. Brar JS, Ganguli R, Pandina G, et al. (2005) Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 66: 205-212.
10. Brown S, Inskip H and Barraclough B (2000) Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 177: 212-217.
11. Center for Disease Control and Prevention (2001) Clinical Growth Charts; Data Table of BMI-for-age Charts. Available at: www.cdc. gov/growthcharts/html- charts/bmiagerev.htm.
12. Cohn T, Prud'homme D, Streiner D, et al. (2004) Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Canadian Journal of Psychiatry 49: 753-760.
13. Cohn TA and Sernyak MJ (2006) Metabolic monitoring for patients treated with antipsychotic medications. Canadian Journal of Psychiatry 51: 492-501.
14. Cook S, Weitzman M, Auinger P, et al. (2003) Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third National Health and Nutrition Examination Survey, 1988-1994. Archives of Pediatrics and Adolescent Medicine 157: 821-827.
15. Correll CU (2006) Real-life switching strategies with second-generation antipsychotics. Journal of Clinical Psychiatry 67: 160-161.
16. Correll CU (2008) Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. Journal of the American Academy of Child & Adolescent Psychiatry 47: 9-20.
17. Correll CU, Harris JL, Pantaleon Moya RA, et al. (2007) Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: Missed targets and lost opportunities. Schizophrenic Research 92: 103-107.
18. Correll CU, Manu P, Olshanskiy V, et al. (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association 302: 1765-1773.
19. Correll CU, Penzner JB, Parikh UH, et al. (2006) Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child and Adolescent Psychiatric Clinics of North America 15: 177-206.
20. Curtis J, Henry C, Watkins A, et al. (2011) Metabolic abnormalities in an early psychosis service: A retrospective, naturalistic cross-sectional study. Early Intervention in Psychiatry 5: 108-114.
21. Curtis J, Newall HD and Samaras K (2012) The heart of the matter: Cardiometabolic care in youth with psychosis. Early Intervention in Psychiatry 6: 347-353.
22. De Hert M, Detraux J, van Winkel R, et al. (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology 8: 114-126.
23. De Hert M, Dobbelaere M, Sheridan EM, et al. (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Journal of Psychiatry 26: 144-158.
24. Desai MM, Rosenheck RA, Druss BG, et al. (2002) Mental disorders and quality of diabetes care in the veterans health administration. American Journal of Psychiatry 159: 1584-1590.
25. Dixon LB, Kreyenbuhl JA, Dickerson FB, et al. (2004) A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses. Psychiatric Services 55: 892-900.
26. Eapen V (2012) Metabolic monitoring for patients on antipsychotic medication: Are we failing to provide reasonable standard of physical healthcare? Evidence-Based Nursing 15: 97-98.
27. Eapen V, Faure-Brac G, Ward PB, et al. (2012) Evaluation of weight gain and metabolic parameters among adolescent psychiatric inpatients: Role of health promotion and life style intervention programs. Journal of Metabolic Syndrome 1: 109.
28. Eapen V and John G (2011) Weight gain and metabolic syndrome among young patients on antipsychotic medication: What do we know and where do we go? Australasian Psychiatry 19: 232-235.
29. Expert Panel on Detection (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association 285: 2486-2497.
30. Foley DL and Morley KI (2011) Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Archives of General Psychiatry 68: 609-616.
31. Frayne SM, Halanych JH, Miller DR, et al. (2005) Disparities in diabetes care: Impact of mental illness. Archives of Internal Medicine 165: 2631-2638.
32. Goldberg RW, Kreyenbuhl JA, Medoff DR, et al. (2007) Quality of diabetes care among adults with serious mental illness. Psychiatric Services 58: 536-543.
33. Haupt DW, Rosenblatt LC, Kim E, et al. (2009) Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. American Journal of Psychiatry 166: 345-353.
34. Hillier TA and Pedula KL (2003) Complications in young adults with early-onset type 2 diabetes: Losing the relative protection of youth. Diabetes Care 26: 2999-3005.
35. Ho J, Panagiotopoulos C, McCrindle B, et al. (2011) Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry 20: 234-241.
36. Holt RI, Abdelrahman T, Hirsch M, et al. (2010) The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. Journal of Psychopharmacology 24: 867-873.
37. International Diabetes Federation (2006) The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Available at: www.idf.org/ webdata/docs/IDF-Meta-def-final.pdf.
38. Jones LE, Clarke W and Carney CP (2004) Receipt of diabetes services by insured adults with and without claims for mental disorders. Medical Care 42: 1167-1175.
39. Kahn RS, Fleischhacker WW, Boter H, et al. (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 371: 1085-1097.
40. Krein SL, Bingham CR, McCarthy JF, et al. (2006) Diabetes treatment among VA patients with comorbid serious mental illness. Psychiatric Services 57: 1016-1021.
41. Kreyenbuhl J, Dickerson FB, Medoff DR, et al. (2006) Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. Journal of Nervous and Mental Disease 194: 404-410.
42. Kwon JS, Choi JS, Bahk WM, et al. (2006) Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. Journal of Clinical Psychiatry 67: 547-553.
43. Lakka HM, Laaksonen DE, Lakka TA, et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Journal of the American Medical Association 288: 2709-2716.
44. Maayan L and Correll CU (2011) Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology 21: 517-535.
45. McEvoy JP, Meyer JM, Goff DC, et al. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80: 19-32.
46. McIntyre RS, McCann SM and Kennedy SH (2001) Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities. Canadian Journal of Psychiatry 46: 273-281.
47. Meyer JM, Nasrallah HA, McEvoy JP, et al. (2005) The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia Research 80: 9-18.
48. Mitchell AJ, Delaffon V, Vancampfort D, et al. (2012) Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychological Medicine 42: 125-147.
49. Mitchell AJ, Malone D and Doebbeling CC (2009) Quality of medical care for people with and without comorbid mental illness and substance misuse: Systematic review of comparative studies. British Journal of Psychiatry 194: 491-499.
50. Morrato EH, Newcomer JW, Kamat S, et al. (2009) Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32: 1037-1042.
51. Myles N, Newall HD, Curtis J, et al. (2012) Tobacco use before, at, and after first-episode psychosis: A systematic meta-analysis. Journal of Clinical Psychiatry 73: 468-475.
52. Nasrallah H (2011) Folie en masse! It's so tempting to drink the Kool-Aid. Current Psychiatry 10: 15-16.
53. Nasrallah HA, Meyer JM, Goff DC, et al. (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86: 15-22.
54. Newcomer JW, Nasrallah HA and Loebel AD (2004) The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: Practice patterns and knowledge of psychiatrists. Journal of Clinical Psychopharmacology 24: S1-6.
55. Organ B, Nicholson E and Castle D (2010) Implementing a physical health strategy in a mental health service. Australasian Psychiatry 18: 456-459.
56. Phillips K, Wood F, Spanou C, et al. (2012) Counselling patients about behaviour change: The challenge of talking about diet. British Journal of General Practice 62: 13-21.
57. Pringsheim T, Panagiotopoulos C, Davidson J, et al. (2011) Evidencebased recommendations for monitoring safety of second generation antipsychotics in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry 20: 218-233.
58. Rose G (1981) Strategy of prevention: Lessons from cardiovascular disease. British Medical Journal (Clinical Research Edition) 282: 1847-1851.
59. Russell JM and Mackell JA (2001) Bodyweight gain associated with atypical antipsychotics: Epidemiology and therapeutic implications. CNS Drugs 15: 537-551.
60. Sacks FM, Bray GA, Carey VJ, et al. (2009) Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. New England Journal of Medicine 360: 859-873.
61. Saddichha S, Ameen S and Akhtar S (2008) Predictors of antipsychotic- induced weight gain in first-episode psychosis: Conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. Journal of Clinical Psychopharmacology 28: 27-31.
62. Scott D and Happell B (2011) The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness. Issues in Mental Health Nursing 32: 589-597.
63. Sernyak MJ (2007) Implementation of monitoring and management guidelines for second-generation antipsychotics. Journal of Clinical Psychiatry 68 Suppl 4: 14-18.
64. Szpakowicz M and Herd A (2008) "Medically cleared": How well are patients with psychiatric presentations examined by emergency physicians? Journal of Emergency Medicine 35: 369-372.
65. Tailor AM, Peeters PH, Norat T, et al. (2010) An update on the prevalence of the metabolic syndrome in children and adolescents. International Journal of Pediatric Obesity 5: 202-213.
66. Taylor D, Young C, Mohamed R, et al. (2005) Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. Journal of Psychopharmacology 19: 182-186.
67. Vancampfort D, Probst M, Sweers K, et al. (2011) Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia. Acta Psychiatrica Scandinavica 123: 423-430.
68. Waterreus AJ and Laugharne JD (2009) Screening for the metabolic syndrome in patients receiving antipsychotic treatment: A proposed algorithm. Medical Journal of Australia 190: 185-189.
69. Weiden PJ, Mackell JA and McDonnell DD (2004) Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research 66: 51-57.
70. Weiss AP, Henderson DC, Weilburg JB, et al. (2006) Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatric Services 57: 1145-1152.
71. Yates T, Davies MJ and Khunti K (2012) Obesity and chronic disease in younger people: An unfolding crisis. British Journal of General Practice 62: 4-5.